IL132537A0 - Truncated vegf-related proteins - Google Patents

Truncated vegf-related proteins

Info

Publication number
IL132537A0
IL132537A0 IL13253798A IL13253798A IL132537A0 IL 132537 A0 IL132537 A0 IL 132537A0 IL 13253798 A IL13253798 A IL 13253798A IL 13253798 A IL13253798 A IL 13253798A IL 132537 A0 IL132537 A0 IL 132537A0
Authority
IL
Israel
Prior art keywords
related proteins
truncated vegf
vegf
truncated
proteins
Prior art date
Application number
IL13253798A
Original Assignee
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collateral Therapeutics filed Critical Collateral Therapeutics
Publication of IL132537A0 publication Critical patent/IL132537A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13253798A 1997-04-25 1998-04-20 Truncated vegf-related proteins IL132537A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
PCT/US1998/007801 WO1998049300A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Publications (1)

Publication Number Publication Date
IL132537A0 true IL132537A0 (en) 2001-03-19

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13253798A IL132537A0 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Country Status (10)

Country Link
EP (1) EP0977854A2 (en)
JP (1) JP2001524828A (en)
KR (1) KR20010020259A (en)
CN (2) CN1260835A (en)
AU (1) AU7250298A (en)
CA (1) CA2287538A1 (en)
EA (1) EA199900861A1 (en)
IL (1) IL132537A0 (en)
NZ (2) NZ514872A (en)
WO (1) WO1998049300A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0751992T3 (en) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2202469T5 (en) 1995-09-08 2011-06-06 Genentech, Inc. PROTEIN RELATED TO VEGF.
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CN1299407A (en) * 1998-03-13 2001-06-13 人体基因组科学有限公司 Vascular endothelial growth factor 2
WO1999049882A2 (en) * 1998-03-27 1999-10-07 Eicher Dorothea J Vegf and vegf-c as infant formula supplements
DE19813774A1 (en) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF)
EP1109823B1 (en) 1998-09-08 2005-11-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ES2229788T3 (en) * 1998-10-26 2005-04-16 Ludwig Institute For Cancer Research USE OF THE VEGF-C OR VEGF-D GENE OR PROTEIN TO PREVENT RESTENOSIS.
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
ATE406907T1 (en) 1998-10-28 2008-09-15 Cornell Res Foundation Inc METHODS FOR REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING TRK RECEPTOR LIGANDS BDNF, NT-3 AND NT-4
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
EP1604024A4 (en) 2000-04-06 2008-04-23 Wayne P Franco Methods of using growth factors for treating heart disease
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
AU8473401A (en) 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7405278B2 (en) 2000-08-10 2008-07-29 Masabumi Shibuya Chimeric human-type vascular endothelial cell growth factor
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
DE60236646D1 (en) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 antibodies
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2005505510A (en) * 2001-06-20 2005-02-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Stimulation of angiogenesis by VEGF-B
KR100967599B1 (en) 2001-10-15 2010-07-05 얀센 파마슈티카 엔.브이. Substituted 4-phenyl-4-1H-imidazol-2-yl-piperidine derivatives for reducing ischaemic damage
EP1827494A4 (en) * 2004-11-18 2010-02-17 Wayne Franco Combination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
EP2385840A4 (en) * 2009-01-07 2012-12-12 Vegenics Pty Ltd Materials and methods for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (en) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
DE69331526T2 (en) * 1992-11-18 2002-10-24 Arch Dev Corp ADENOVIRUS GUIDED GEN TRANSFER TO HEART AND SMOOTH VASCULAR MUSCLE
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
JP3961019B2 (en) * 1995-02-28 2007-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Gene transfer mediated angiogenesis therapy
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0815221B1 (en) * 1995-03-02 2003-10-22 AMRAD Operations Pty.,Ltd. A novel growth factor and a genetic sequence encoding same
CA2224002A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Also Published As

Publication number Publication date
EP0977854A2 (en) 2000-02-09
EA199900861A1 (en) 2000-06-26
CA2287538A1 (en) 1998-11-05
CN1260835A (en) 2000-07-19
AU7250298A (en) 1998-11-24
KR20010020259A (en) 2001-03-15
WO1998049300A3 (en) 1999-03-11
JP2001524828A (en) 2001-12-04
WO1998049300A2 (en) 1998-11-05
NZ500530A (en) 2001-12-21
NZ514872A (en) 2005-01-28
CN1680442A (en) 2005-10-12

Similar Documents

Publication Publication Date Title
IL132537A0 (en) Truncated vegf-related proteins
GB9718609D0 (en) Fusion protein
PT1090128E (en) Modified vitamin-k-dependent polypeptides
ZA9810716B (en) Novel polypeptides
ZA9710338B (en) Proteins
IL133582A0 (en) Mammalian neuro-growth factor like protein
GB9703681D0 (en) Protein complemention
GB9719879D0 (en) Protein
EP1018551A4 (en) Megsin protein
GB9718110D0 (en) Peptides
GB9701710D0 (en) Mammalian protein
ZA984322B (en) Sucrose-binding proteins
GB9700154D0 (en) Peptides
GB9720784D0 (en) Protein
EP0996457A4 (en) Fsh-releasing peptides
EP1037898A4 (en) Secreted proteins
AU2002300742A1 (en) Truncated Vegf-related Proteins
EP1127066A4 (en) Modified proteins
GB9722003D0 (en) Proteins
GB9700121D0 (en) Proteins
GB9703104D0 (en) Proteins
GB9722727D0 (en) Proteins
GB9707822D0 (en) Proteins
GB9707499D0 (en) Proteins
GB9604865D0 (en) Modified proteins